Netspot 40 mcg Kit ; Powder For Solution is a Health Canada–registered radiopharmaceutical drug (DIN 02490005) held by Novartis Pharmaceuticals Canada Inc, containing Oxodotreotide. Health Canada lists its status as Marketed (status date 28 Feb 2024). Nexara Health has matched 3 registrations of Oxodotreotide across 2 other regulated markets.
Health Canada registration
| DIN | 02490005 |
|---|---|
| Brand name | Netspot |
| Active ingredient | Oxodotreotide |
| Strength | 40 mcg |
| Dosage form | Kit ; Powder For Solution |
| Route | Intravenous |
| Company | Novartis Pharmaceuticals Canada Inc |
| Status | Marketed — 28 Feb 2024 |
| Class | Radiopharmaceutical |
| ATC | V09I TUMOUR DETECTION |
| AHFS | 38:00.00 |
| Regulator record | Health Canada DPD entry · Product monograph |
Oxodotreotide registered in other markets
3 registrations of the same molecule in 2 national registries outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| European Union (EMA) | Deqtynet | CIS bio international | Refused | EMA centrally authorised | ||
| United States | Oxodotreotide | piCHEM Forschungs-und Entwicklungs GmbH | Powder | FDA NDC | ||
| United States | Oxodotreotide | piCHEM Forschungs-und Entwicklungs GmbH | Powder | FDA NDC |
See every manufacturer of Oxodotreotide worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Netspot (DIN 02490005) marketed in Canada?
Yes. Health Canada lists DIN 02490005 as Marketed as of 28 Feb 2024.
Who holds the Canadian licence for this product?
Novartis Pharmaceuticals Canada Inc is the company of record in the Health Canada Drug Product Database.
Is Oxodotreotide registered outside Canada?
Yes — Nexara Health has matched 3 registrations in 2 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02490005, status date 2024-02-28; national medicine registries: EMA centrally authorised, FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02490005, status date 2024-02-28; national medicine registries: EMA centrally authorised, FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02490005, status date 2024-02-28; national medicine registries: EMA centrally authorised, FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.